Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles
about
Human papillomavirus infection requires cell surface heparan sulfate.Prophylactic human papillomavirus vaccinesThe history of tumor virologyHuman papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital wartsIdentification of the alpha6 integrin as a candidate receptor for papillomavirusesSelf-assembling protein nanoparticles in the design of vaccinesPapillomavirus Infectious Pathways: A Comparison of SystemsHuman papillomavirus vaccination: a case study in translational scienceConcatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesRNA is a structural element in retrovirus particlesIn vivo and in vitro association of hsc70 with polyomavirus capsid proteins.Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly.Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines.Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16.Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein.Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses.Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.The role of vaccines in the control of STDs: HPV vaccines.Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay.Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.Diffusion of macromolecules and virus-like particles in human cervical mucusEnhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirusA novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.Interactions between papillomavirus L1 and L2 capsid proteinsHuman papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.Genital human papillomavirus infectionPolymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responsesOral immunogenicity of human papillomavirus-like particles expressed in potato.Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.How will HPV vaccines affect cervical cancer?The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.
P2860
Q24529079-A88F02E1-C9B6-43B1-866B-950367BBD1D6Q24545449-7B7069E0-91F5-41A3-B24D-061702D1D6A5Q24610004-D33BCB2C-14E6-4655-BBD2-2C6880596C01Q24645760-960A8B58-1F86-40C6-B4DD-934D21003C9CQ24678291-ACBB5D84-393F-47B5-BDBF-4A6A825EDF1FQ26767097-3C27AD07-7BB8-4831-BB3B-8C5D7E6FD291Q26801497-0AFED6E1-31FC-41A9-8DC7-77F7BAF0B33EQ26853556-8B3FE053-8AA7-45C9-A871-4C0986E43404Q28246307-7522565D-536C-475D-A9B5-779C9ED88EA6Q30054778-5FD4C0F0-EDBD-4523-B51E-F96013B540A6Q30452603-542CEE51-6378-478E-923A-A5A2382BC0D4Q33707499-BE0FDFEC-D22F-4B18-B802-7C697D4E0D14Q33782413-3E99B5AC-047F-4EAB-882F-21B12E578DA3Q33785841-2957025C-154C-410F-85A6-BC416A36E20BQ33785870-8F701768-3E5B-4B30-8084-A3D5E57F10DDQ33787204-D0423466-DDC5-4FE3-910F-A93840B62198Q33834481-26018F96-E9A6-490B-8666-4DA31EEF7139Q33840918-0A195932-DC02-4EA8-AC46-49FF95F94762Q33847557-8D508387-D763-4051-8E06-395120BED6D4Q33850734-9284BAD2-A5E1-48BD-885F-F13AA694B7F0Q33908917-E427B7E6-EB25-4573-B847-1272F1CF3249Q33936363-3E2F3B4B-11F8-4AAD-833F-CA0B1D2C1E45Q33943463-08CEBB52-5EB0-4139-A720-5B0A71640857Q33950282-72C3285E-BF87-431A-ADD2-BC993656CFA5Q34069054-5B22B58E-DF9C-4D21-A34D-408EEE259F4DQ34075698-68539B8B-7B0E-48F1-9C8D-F794829B831AQ34176484-13E0B4BE-43E1-4EDE-AE83-B36FA4789826Q34203433-68A9153A-AF76-4746-B9EF-5564A184097DQ34593100-E36B57F8-3857-4E1A-BF87-BCF0D4EC65DBQ34639978-B37CC7A7-8BEC-46FD-BBD0-A68189FB9FE4Q34860943-A3A8FA6A-D3CF-4008-A0E5-0227453A0651Q34995733-1DFED47F-71A7-4DD6-8880-C7A93737DE23Q35079915-225BC0A8-364F-492A-A76C-7C2D28C7F9CBQ35114105-E0191F84-8D58-4012-BAA0-E3FF8BBB050CQ35155632-EC6546DD-8ACA-483A-9A89-CF3445C53ACBQ35182055-416D7881-0E1B-4FD1-8626-0D5E6E5E75C2Q35227072-D158F40A-6E65-4980-A85A-0AA641ADAD85Q35228978-81F439D1-F177-478C-8986-92C4B3057E65Q35235035-DAF17465-5E2E-46D2-BC11-AC750B698369Q35541210-8C24CD75-DA97-4305-A804-AE043C3DDFA0
P2860
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Expression of human papillomav ...... ssembly of viruslike particles
@ast
Expression of human papillomav ...... ssembly of viruslike particles
@en
type
label
Expression of human papillomav ...... ssembly of viruslike particles
@ast
Expression of human papillomav ...... ssembly of viruslike particles
@en
prefLabel
Expression of human papillomav ...... ssembly of viruslike particles
@ast
Expression of human papillomav ...... ssembly of viruslike particles
@en
P2093
P2860
P1433
P1476
Expression of human papillomav ...... ssembly of viruslike particles
@en
P2093
P2860
P304
P407
P577
1993-04-01T00:00:00Z